Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Intrinsic Value
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CRXT.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Clarus Therapeutics Holdings Inc's business.
What risks and challenges
does Clarus Therapeutics Holdings Inc face in the near future?
Summarize the latest earnings report
of Clarus Therapeutics Holdings Inc.
Provide P/E
for Clarus Therapeutics Holdings Inc and its competitors.
Balance Sheet Decomposition
Clarus Therapeutics Holdings Inc
Current Assets | 48.9m |
Cash & Short-Term Investments | 19.2m |
Receivables | 8.7m |
Other Current Assets | 21m |
Non-Current Assets | 60k |
PP&E | 60k |
Current Liabilities | 61.8m |
Accounts Payable | 8.5m |
Accrued Liabilities | 9.8m |
Other Current Liabilities | 43.5m |
Non-Current Liabilities | 197k |
Other Non-Current Liabilities | 197k |
Earnings Waterfall
Clarus Therapeutics Holdings Inc
Revenue
|
16.9m
USD
|
Cost of Revenue
|
-3.6m
USD
|
Gross Profit
|
13.3m
USD
|
Operating Expenses
|
-53.2m
USD
|
Operating Income
|
-39.9m
USD
|
Other Expenses
|
7.3m
USD
|
Net Income
|
-32.6m
USD
|
Free Cash Flow Analysis
Clarus Therapeutics Holdings Inc
What is Free Cash Flow?
CRXT Profitability Score
Profitability Due Diligence
Clarus Therapeutics Holdings Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Clarus Therapeutics Holdings Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
CRXT Solvency Score
Solvency Due Diligence
Clarus Therapeutics Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Clarus Therapeutics Holdings Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRXT Price Targets Summary
Clarus Therapeutics Holdings Inc
Ownership
CRXT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRXT Price
Clarus Therapeutics Holdings Inc
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -100% |
Market Capitalization | 1.1m USD |
Shares Outstanding | 52 020 700 |
Percentage of Shares Shorted | 6.89% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Northbrook, Illinois and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is focused on the commercialization of JATENZO, an oral T-replacement, or T-replacement therapy (TRT). The Company’s lead product, JATENZO, an androgen indicated for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. In addition, JATENZO focuses on the classic signs and symptoms associated with hypogonadism, including psychosexual symptoms, body mass index, fat mass and bone mineral density. The firm plans to focused on the development and commercialization of T and metabolic therapies for men and women.